News & Updates

DPP-4–to–SGLT2 inhibitor switch confers multiple benefits for patients with diabetes, hypertension
DPP-4–to–SGLT2 inhibitor switch confers multiple benefits for patients with diabetes, hypertension
28 Sep 2021 byJairia Dela Cruz

In the treatment of patients with type 2 diabetes mellitus and hypertension, switching from a dipeptidyl peptidase-4 (DPP-4) inhibitor to the sodium-glucose cotransporter-2 (SGLT2) inhibitor luseogliflozin appears to have favourable effects on blood pressure (BP), circadian rhythm, and night-time systolic BP (SBP) and pulse rate (PR), according to data from the open-label LUNA trial.

DPP-4–to–SGLT2 inhibitor switch confers multiple benefits for patients with diabetes, hypertension
28 Sep 2021
Side effects limit long-term therapy for primary aldosteronism
Side effects limit long-term therapy for primary aldosteronism
28 Sep 2021
High-flowrate air samplers allow thorough monitoring for airborne SARS-CoV-2
High-flowrate air samplers allow thorough monitoring for airborne SARS-CoV-2
28 Sep 2021 byTristan Manalac

High-flowrate air samplers are able to detect airborne SARS-CoV-2 in hospitals, outperforming even surface sampling, according to a recent Singapore study. Factors such as the site of deployment and distance of the air samplers from patients affect the viral load detected.

High-flowrate air samplers allow thorough monitoring for airborne SARS-CoV-2
28 Sep 2021